FDA has accepted and granted priority review for a new supplemental Biologics License Application for Keytruda as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
